Tag: litigation

CELEBRATION, Fla., July 28, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare diseases, announced the company submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for the evaluation of arimoclomol for the treatment of Niemann-Pick Disease Type C (NPC). NPC is an ultra-rare, neurological disease caused by genetic mutations that result in lipid accumulation in cells, leading to visceral, neurological, and psychiatric symptoms. Arimoclomol is the only treatment shown to directly target the underlying pathology of NPC by increasing gene expression for improved lipid clearance. Arimoclomol for the treatment of NPC has been designated as an Orphan Medicinal Product by the EMA. Arimoclomol is marketed in the U.S. under the brand name MIPLYFFA®.

新加坡, July 28, 2025 (GLOBE NEWSWIRE) -- OMS Energy Technologies Inc. (简称“OMS”或“公司”) (NASDAQ：OMSE) 是一家专注于为油气行业生产地面井口系统 (“SWS”) 和石油管材产品 (“OCTG”) 的增长型企业，今日，公司公布了其截至 2025 年 3 月 31 日的 2025 财年财务业绩。

SINGAPORE, July 28, 2025 (GLOBE NEWSWIRE) -- OMS Energy Technologies Inc. (“OMS” or the “Company”) (NASDAQ: OMSE), a growth-oriented manufacturer of surface wellhead systems (“SWS”) and oil country tubular goods (“OCTG”) for the oil and gas industry, today announced its financial results for the fiscal year ended March 31, 2025.

NEW YORK, July 27, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Vera Bradley, Inc. (NASDAQ: VRA) resulting from allegations that Vera Bradley may have issued materially misleading business information to the investing public.

NEW YORK, July 26, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Simulations Plus, Inc. (NASDAQ: SLP) resulting from allegations that Simulations Plus may have issued materially misleading business information to the investing public.

卡尔霍恩，佐治亚州, July 26, 2025 (GLOBE NEWSWIRE) -- Mohawk Industries, Inc. (NYSE: MHK) 今日宣布，公司 2025 年第二季度净收益为 1.47 亿美元，每股收益 (EPS) 为 2.34 美元；调整后净收益为 1.73 亿美元，调整后每股收益为 2.77 美元。 2025 年第二季度净销售额为 28 亿美元，按报告口径同比基本持平，按恒定工作日与汇率调整后同比下降 0.8%。 2024 年第二季度，公司报告净销售额 28 亿美元、净收益 1.57 亿美元、每股收益 2.46 美元；调整后净收益为 1.92 亿美元，调整后每股收益为 3.00 美元。